https://www.avient.com/sites/default/files/resources/Investor%2520Presentation%2520Mar19.pdf
Non-GAAP financial measures have
limitations as analytical tools and should not be considered in isolation from, or solely as alternatives to, financial measures prepared in accordance with GAAP.
Adjusted EPS attributable to PolyOne common shareholders is calculated as follows:
2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016 2017 2018
Net income from continuing operations attributable to
PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1
Joint venture equity earnings, after tax (19.0) (14.7) (3.7) — — — — — — —
Special items, before tax(1) (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5
Special items, tax adjustments(1) (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3)
Adjusted net income from continuing operations
attributable to PolyOne common shareholders $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3
Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4
Adjusted EPS attributable to PolyOne common
shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43
* Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation
Tax adjustments include the net tax benefit/(expense) from one-time income tax items, the set-up or reversal of uncertain tax position
reserves and deferred income tax valuation allowance adjustments.
https://www.avient.com/products/polymer-additives/visual-enhancement-effects/cesa-bright-optical-brighteners
Find your ideal solution in our broad portfolio of solid or liquid colorants.
Browse and download our literature to learn more about Avient solutions and services.
Important information about the health, safety and environmental impacts of Avient products.
https://www.avient.com/news/‘future-proof’-pharma-packaging-avient-launches-new-regulatory-compliant-mevopur-amber-masterbatches
Produced under rigorous cGMP and medical manufacturing protocols, the new amber color concentrates are made in three dedicated EN ISO 13485-2016 registered facilities using only medical-grade ingredients.
The new MEVOPUR concentrates block wavelengths from 290 – 450 nm, while still providing good transparency.
Avient can design these concentrates in a range of amber tones from light to dark, and with more or less red or yellow.
https://www.avient.com/products/long-fiber-technology/complet-long-glass-fiber
In conjunction with the advantages of organic design possibilities from the injection molding forming process, it is common to see a 40-50% weight reduction in applications when switching from metal incumbents (aluminum, magnesium).
Our long glass fiber reinforced products range from 20-70% fiber content (by weight) across a variety of resin systems ranging from polypropylene to higher performance engineering polymers such as PEEK.
Complēt™ LGF, moisture-resistant grade delivers improved performance and cost savings for aftermarket parts manufacturer
https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520-%2520Goldman%2520Sachs%2520Conference%2520w%2520nonGAAP.pdf
They are based on management’s expectations that involve a number of business risks and uncertainties, any of which
could cause actual results to differ materially from those expressed in or implied by the forward-looking statements.
S&P 500
-150%
-50%
50%
150%
250%
350%
450%
550%
POL S&P 500
All time high of
$43.34
July 1st, 2014
PolyOne Corporation Page 9
2006 2014 YTD 2015
“Where we were” “Where we are” Target
1) Operating Income %
Specialty:
Global Color, Additives & Inks 1.7% 14.9% 12 – 16%
Global Specialty Engineered
Materials 1.1% 12.1% 12 – 16%
Designed Structures & Solutions -- 7.6% 8 – 10%
Performance Products &
Solutions 5.5% 8.1% 9 – 12%
Distribution 2.6% 6.2% 6 – 7.5%
2) Specialty Platform % of
Operating Income 6.0% 65% 65 – 75%
3) ROIC* 5.0% 10.6% 15%
4) Adjusted EPS Growth N/A 37% Double Digit
Expansion
Proof of Performance & 2015 Goals
*ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period
PolyOne Corporation Page 10
32% Adjusted EPS CAGR from 2011
2015 EPS: $2.50
2011 EPS: $0.82
Continued Gross Margin
Expansion
Mergers & Acquisitions
Spartech Accretion
Incremental Share Buybacks
Ongoing LSS Programs
(50-100 bps/yr)
Accelerated Innovation
& Mix Improvement Several Levers to
Drive Growth
Mid Single Digit Revenue Growth
PolyOne Corporation Page 11
Innovation Drives Earnings Growth
*Percentage of Specialty Platform revenue from products introduced in last five years
$20
$53
2006 2013
Research & Development
Spending
($ millions)
Specialty Platform
Vitality Index Progression*
14%
31%
2006 2013
Specialty Platform
Gross Margin %
20%
43%
2006 2013
Specialty Vitality Index Target ≥ 35%
Vitality Products
+ 700 to 1000 bps
PolyOne Corporation Page 12
Prototype Frame
Opportunity
Scale-up &
Test Market
Build
Business Case
Commercial
Launch
Phase
1
Phase
2
Phase
3
Phase
4
Phase
5
4
11
5
10
6
9
3 4 2
15
9
1
10
4
Breakthrough
Platform
Derivative
A Rich Pipeline of Opportunity
Number of Projects 25 14 19 17 18 93
Addressable Market
($ millions) TBD TBD $800 $450 $450 $1,700
PolyOne Corporation Page 13
Megatrends Aligned with Key End Markets
Decreasing
Dependence
on Fossil
Fuels
Protecting
the
Environment
Improving
Health and
Wellness
Megatrend End Markets
Globalizing
and
Localizing
Health &
Wellness
Transportation
Packaging
Consumer
PolyOne Corporation Page 14
60%
100%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2008 2014
Pension Funding**
As of September 30, 2014
Debt Maturities & Pension Funding – 9/30/14
Net Debt / EBITDA* = 1.7x
$48
$317
$600
$0
$100
$200
$300
$400
$500
$600
$700
$800
2015 2020 2023
Debt Maturities
As of September 30, 2014
($ millions)
Coupon Rates: 7.500% 7.375% 5.250%
** includes US-qualified pension plans only *TTM 9/30/2014
PolyOne Corporation Page 15
Free Cash Flow and Strong Balance Sheet
Fund Investment / Shareholder Return
Expanding our sales, marketing,
and technical capabilities
Targets that expand our:
• Specialty offerings
• End market presence
• Geographic footprint
• Operating Margin
Synergy opportunities
Adjacent material solutions
Repurchased 1.5 million shares in
Q3 2014
Repurchased 9.7 million
shares since early 2013
10.3 million shares are
available for
repurchase under the
current authorization
Organic
Growth
Acquisitions
Share
Repurchases
Dividends
Investing in operational and
LSS initiatives (including
synergy capture)
Manufacturing alignment
$0.16
$0.20 $0.24
$0.32
$0.40
$0.10
$0.20
$0.30
$0.40
$0.50
2011 2012 2013 2014 2015
Annual Dividend
PolyOne Corporation Page 16
PolyOne Core Values
Innovation
Collaboration
Excellence
PolyOne Corporation Page 17
The New PolyOne: A Specialty Growth Company
Why Invest In PolyOne?
��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�November 20, 2014��
Forward-Looking Statements
Use of Non-GAAP Measures
PolyOne Commodity to Specialty Transformation
PolyOne�At A Glance
Mix Shift Highlights Specialty Transformation
Confirmation of Our Strategy
Strategy and Execution Drive Results
Proof of Performance & 2015 Goals
32% Adjusted EPS CAGR from 2011
Innovation Drives Earnings Growth
A Rich Pipeline of Opportunity
Megatrends Aligned with Key End Markets
Debt Maturities & Pension Funding – 9/30/14
Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return
PolyOne Core Values
Why Invest In PolyOne?
https://www.avient.com/sites/default/files/2024-07/TPE Whitepaper_0.pdf
TPEs also allow for greater
design freedom, an extended product portfolio
and lower extractables.
Medical
grade TPEs have extremely low levels of leachables and extractables, and
are available in several different formulations to address specific processing
and end product requirements.
4© 2020 Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012
CASE IN POINT: STOPPERS AND SEPTUMS
Versaflex™ HC TPE from Avient offers customers an exceptional
alternative to rubber for septums and stoppers.
They may enable you to bolster
your sustainability profile by removing potentially harmful chemicals
from your process.
https://www.avient.com/industries/healthcare/medical-devices-equipment
Our medical-grade polymer technologies and technical support services are focused on helping you solve short- and long-term product challenges.
Avient Design
Sync design with manufacturability: Learn about how Avient Design can help simplify your new product development process
https://www.avient.com/news/demanding-applications-new-polyone-tpe-nylon-grips-improves-oil-and-abrasion-resistance
Avient Announces Quarterly Dividend...
Avient Board of Directors Appoints Ashish K.
Avient Announces First Quarter 2025 Results...
https://www.avient.com/knowledge-base/article/how-perfect-thermal-management-led-lighting-applications
Polymers can improve heat management, reduce weight, and expand design freedom
Case Study LED Manufacturer Innovates and Saves with Polymer Heat Sinks
Shift from metal drives improved product line for component manufacturer
Read More
May 30, 2015
https://www.avient.com/knowledge-base/article/how-perfect-thermal-management-led-lighting-applications?rtype[]=1164
Polymers can improve heat management, reduce weight, and expand design freedom
Case Study LED Manufacturer Innovates and Saves with Polymer Heat Sinks
Shift from metal drives improved product line for component manufacturer
Read More
May 30, 2015